A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
Latest Information Update: 15 Sep 2022
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms TRACE
- Sponsors Actelion Pharmaceuticals
- 08 Sep 2022 Results published in the Chest
- 21 Oct 2020 Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 17 Mar 2020 Status changed from active, no longer recruiting to completed.